Researchers have examined the adverse outcomes of zafirlukast in Older people and children aged twelve or more mature. Occasional studies of eosinophilia accompanied by vasculitis in patients on zafirlukast have emerged. Zafirlukast is thoroughly hepatically metabolized by an enzyme named CYP2C9.